Study: NCT01352650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles